Canaccord raised the firm’s price target on Arcellx to $85 from $66 and keeps a Buy rating on the shares. The firm said Arcellx remains on track for top-line Phase 2 iMMagine-1 data for antio-cel by year-end 2024, where we expect significant upside. Canaccord expects completion of enrollment during 2024 and initiation of the earlier line iMMagine-2 study for antio-cel.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ACLX: